Climb Bio (CLYM) Stock Price, News & Analysis

Company Overview

Climb Bio Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria.

Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability.

Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.

Key Stats

• Today's Range: $10.64 to $11.27
• 50-Day Range: $6.11 to $12.22
• 52-Week Range: $1.16 to $12.48
• Volume: 454,122 shs
• Average Volume: 945,215 shs
• Market Capitalization: $629.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.30
• Consensus Rating: Buy

Climb Bio Stock Analysis - MarketRank™

Climb Bio scored higher than 60% of companies evaluated by MarketBeat, and ranked 362nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Climb Bio has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 3 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Climb Bio has a consensus price target of $20.30, representing about 84.5% upside from its current price of $11.00.

Amount of Analyst Coverage

Climb Bio has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Climb Bio are expected to decrease in the coming year, from ($0.89) to ($1.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Climb Bio is -14.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Climb Bio is -14.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Climb Bio has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.19% of the float of Climb Bio has been sold short.

Short Interest Ratio / Days to Cover

Climb Bio has a short interest ratio ("days to cover") of 2.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Climb Bio has recently increased by 10.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Climb Bio does not currently pay a dividend.

Dividend Growth

Climb Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.30

News Sentiment

Climb Bio has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Climb Bio this week, compared to 4 articles on an average week.

Search Interest

Only 14 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

9 people have added Climb Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Climb Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.60% of the stock of Climb Bio is held by insiders.

Percentage Held by Institutions

69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/25/2026
• Jefferies Global Healthcare Conference 2026: 6/04/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLYM
• Previous Symbol: NASDAQ:CLYM
• CIK: 1768446
• Web: climbbio.com
• Phone: 866-857-2596
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Climb Bio: $20.30
• High Price Target: $26.00
• Low Price Target: $17.00
• Potential Upside/Downside: +84.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.45%
• Return on Assets: -30.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.86
• Quick Ratio: 27.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 4.25

Miscellaneous

• Outstanding Shares: 57,260,000
• Free Float: 55,772,000
• Market Cap: $629.86 million
• Optionable: N/A
• Beta: 0.02